tarlatamab–durvalumab maintenance therapy achieved a median overall survival of 21.1 months in a prespecified interim analysis of a phase 3 trial. Durvalumab alone resulted in a median overall survival of 12.7 months. The data are from the DeLLphi-305 trial presented at ESMO 26.
Key points
Median overall survival: 21.1 months with tarlatamab–durvalumab maintenance.
Median overall survival: 12.7 months with durvalumab alone.
Sources
- Original post
- nej.md - Linked in the post
Ultra Mobility Vehicle robot adds jumps, wheelies
Ultra Mobility Vehicle bicycle robot adds jumps, wheelies and other athletic moves using its own inertia and momentum. It can also perform track stands and other athletic moves.
Key points
Feature: leverages its own inertia and momentum to perform jumps
Capability: can do track stands, wheelies and other athletic moves
Sources
- Original post
- scim.ag - Linked in the post
Hafnium oxide interface stabilization – Erratum replaces July 2026 Expression of Concern
Hafnium oxide interface stabilization for efficient, photothermally stable perovskite solar cells receives an Erratum. The Erratum replaces the July 2026 Editorial Expression of Concern for the February 2026 research article.
Key points
Erratum published by Science
Replaces July 2026 Editorial Expression of Concern for the February 2026 article
Sources
- Original post
- scim.ag - Linked in the post
Osimertinib–Savolitinib phase 3 SAFFRON trial in advanced NSCLC
Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy is a phase 3 SAFFRON trial. The trial evaluates the drug combination for patients whose disease progressed on EGFR-TKI therapy.
Key points
Phase 3 SAFFRON trial
Osimertinib–Savolitinib combination for advanced NSCLC after EGFR-TKI progression
Sources
- Original post
- nej.md - Linked in the post
Stem cell transplant immune suppression analysis shows opposing effects
Stem cell transplant recipients analysis shows immune suppression with cyclophosphamide or tacrolimus shapes T cell reconstitution. The two drugs have opposite impacts on graft-versus-host disease risk and infection risk.
Key points
Cyclophosphamide shapes T cell reconstitution and affects GVHD risk.
Tacrolimus shapes T cell reconstitution and affects infection risk.
Sources
- Original post
- scim.ag - Linked in the post
